GSK Receives “Complete Response” Letter For Cervarix BLA
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug maker will respond to FDA “as soon as possible” to answer outstanding questions related to the HPV vaccine.
You may also be interested in...
A Shot in the Arm? FDA Committee To Review Merck and Glaxo HPV Vaccines
For Merck, the outcome may mean a long-awaited move to market Gardasil to males; for Glaxo, this may be its chance to sell Cervarix in the U.S.
A Shot in the Arm? FDA Committee To Review Merck and Glaxo HPV Vaccines
For Merck, the outcome may mean a long-awaited move to market Gardasil to males; for Glaxo, this may be its chance to sell Cervarix in the U.S.
GSK’s Responds To FDA On Cervarix, Will Augment BLA With More Efficacy Data
Firm will send final study data on the cervical cancer vaccine to FDA in the first half of 2009, and approval could come six months later.